6836-48-2

Usage

Uses

Used in Pharmaceutical Development:
Naphthalene, 6-(bromomethyl)-1,2,3,4-tetrahydrois utilized as a key intermediate in the synthesis of various drug molecules. Its unique structure allows for the creation of new compounds with potential therapeutic applications.
Used in Agrochemical Synthesis:
Naphthalene, 6-(bromomethyl)-1,2,3,4-tetrahydroalso serves as a building block in the development of agrochemicals, contributing to the creation of new products for agricultural use.
Used in Organic Chemistry Reactions:
Naphthalene, 6-(bromomethyl)-1,2,3,4-tetrahydrofunctions as a reagent in a range of organic chemistry reactions, facilitating the synthesis of complex organic molecules for research and industrial applications.

Upstream product

• 6883-81-4 6-hydroxymethyl-1,2,3,4-tetrahydronaphthalene 
• 23194-33-4 methyl 5,6,7,8-tetrahydronaphthalene-2-carboxylate 
• 1131-63-1 1,2,3,4-tetrahydro-2-naphthoic acid 

Downstream Products

• 53618-53-4 (5,6,7,8-Tetrahydro-naphthalen-2-ylmethanesulfinyl)-acetic acid 4-nitro-benzyl ester 
• 53618-54-5 (5,6,7,8-Tetrahydro-naphthalen-2-ylmethanesulfinyl)-acetic acid 2-(4-bromo-phenyl)-2-oxo-ethyl ester 
• 166519-73-9 (2S,4R)-2-[(S)-1-(Benzyl-methyl-carbamoyl)-2-(5,6,7,8-tetrahydro-naphthalen-2-yl)-ethylcarbamoyl]-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 158574-75-5 [(S)-1-(Benzyl-methyl-carbamoyl)-2-(5,6,7,8-tetrahydro-naphthalen-2-yl)-ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Discovery of Benzocycloalkane Derivatives Efficiently Blocking Bacterial Virulence for the Treatment of Methicillin-Resistant S. aureus (MRSA) Infections by Targeting Diapophytoene Desaturase (CrtN)

Antivirulence strategies are now attracting interest for the inherent mechanism of action advantages. In our previous work, diapophytoene desaturase (CrtN) was identified to be an attractive and drugable target for fighting pigmented S. aureus infections. In this research, we developed a series of effective benzocycloalkane-derived CrtN inhibitors with submicromolar IC50. Analogue 8 blocked the pigment biosynthesis of three MRSA strains with a nanomolar IC50 value. Corresponding to its mode of action, 8 did not function as a bactericidal agent. 8 could sensitize S. aureus to immune clearance. In vivo, 8 was proven to be efficacious in an S. aureus Newman sepsis model and abscess formation model. For two typical MRSAs, USA400 MW2 and Mu50, 8 significantly decreased the staphylococcal loads in the liver and kidneys. Moreover, 8 showed minimal antifungal activity compared to that of NTF. In summary, 8 has the potential to be developed as a therapeutic drug, especially against intractable MRSA issues.